_______________________________________
FREE Daily Stock Alerts From CRWEWallStreet.com
_______________________________________
HOUSTON, (CRWENEWSWIRE) 03/02/2010 - Power3 Medical Products, Inc. (OTCBB:PWRM) announced that 4 abstracts covering results from clinical validation trials of the NuroPro® AD test for Alzheimer’s disease were submitted to the 2010 annual meeting of the International Congress of Alzheimer’s Disease, taking place July 2010. The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from “normal” individuals and patients with other neurological disorders. The test, developed by Power3, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer’s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.
The four studies present the capabilities of NuroPro for accurate diagnosis, targeted therapy and drug response monitoring. They involve a total of 154 Alzheimer’s disease and 91 Parkinson’s disease patients, 210 age-matched normal and 173 disease control individuals. The abstracts report the combined results from the clinical validation trials of the NuroPro® AD and NuroPro PD tests, conducted by the Power3 scientific team, led by medical director Lourdes R. Bosquez, MD and chief scientific officer, Ira L. Goldknopf, Ph.D., in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute, Sun City, Arizona, Katerina Markopoulou, M.D., Assistant Professor of Neurology at the University of Thessaly, Larissa Greece, along with previous studies Power3 conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology, Baylor College of Medicine, Houston TX. Dr. Appel is now Co-Director of the Methodist Neurological Research Institute, Houston, TX, and continues to be chairman of the scientific advisory board of Power3.
“To date we have not been successful in treating dementia because of the complexity of the diagnosis,” said Dr. Bosquez, Power3’s medical director. “These studies show how the NuroPro AD test can specifically diagnose Alzheimer’s disease and also address patient to patient differences. One size does not fit all.”
“Treatment of Alzheimer’s disease has a greater chance of success if it is detected in its earliest stages. As a neurologist and a clinician I am excited at the potential of having this diagnostic tool to detect Alzheimer’s disease and ultimately producing better outcomes and quality of life for those who suffer from the disease,” says Marwan Sabbagh M.D., director of clinical research at Banner Sun Health Research Institute.
About Power3 Medical Products, Inc.
Power3 Medical Products, http://www.Power3Medical.com, is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.
For more information, visit http://www.Power3Medical.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company’s actual results to differ materially from those indicated in any forward-looking statements.
Contact:
Crown Equity Holdings, Inc.
877 854-6797
702 448-1543
************Advertisement************
.png)
.png)
.png)
************************************
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).
